BÖLÜM 10

Özofagus-Mide-İnce Bağırsak ve Pankreatobilier Sistem Tümörlerinde F-18 Florodeoksiglukoz, Ga-68 DOTATATE ve FAPI Pozitron Emisyon Tomografisi/Bilgisayarlı Tomografi

Zehra Pınar KOÇ[1]

Giriş

Üst gastrointestinal sistem ve pankreatobilier sistem tümörlerinde F-18 izotopu ile işaretlenmiş fluoro-2-deoksi-glikoz Pozitron Emisyon Tomografisi/Bilgisayarlı Tomografi (FDG PET/BT) ve *Galyum 68* (Ga-68) DOTATATE VE FAPI PET/BT görüntüleme, her ne kadar özellikle pankreatobilier sistemde çalışmalar sürmekte ise de gittikçe artan bir rol kazanmaktadır. Bu tetkiklerin kendine özel sınırlılıkları bulunmakla birlikte, lezyona spesifik görüntüleme yöntemleri olmasının doğal üstünlüklerini de barındırmaktadır. Üst gastrointestinal sistem (özofagus-mide-ince bağırsak) tümörlerinde özellikle primer kitleye ait yoğun aktivite tutulumu nedeniyle peritümöral lenf nodlarında rölatif kısıtlılıkları olsa da beklendiği gibi uzak metastazların tespit edilmesi, tedavi yanıtı değerlendirmesi, prognoz tespiti ve özellikle neoadjuvan kemoterapi sonrası operabilite değerlendirmesinde FDG PET/BT'nin hasta yönetimine önemli katkılar sağladığı bilinmektedir. Bundan sonra yapılacak çalışmalar şu anda olduğu gibi, bu alandaki gelecek vadeden görüntüleme yönteminin FAPI PET/BT olduğuna işaret etmektedir.

Özefagus Karsinomu

Üst gastrointestinal sistem tümörlerinde son yapılan çalışmalar özellikle T evreleme ve bölgesel lenf nodların tespitinde FDG PET/BT'nin kısıtlılıkları nedeniyle bu alanlarda tanının Endoskopik Ultrasonografi (EUS) ve ince iğne aspirasyon biyopsileri ile desteklenmesi gerektiğini göstermektedir (1, 2). Son yıllarda PET/BT cihazlarıyla birlikte Pozitron Emisyon Tomografisi/Manyetik Rezonans (PET/MR) görüntüleme sistemlerinin

[1] Prof Dr., Mersin Üniversitesi Tıp Fakültesi Nükleer Tıp ABD, zehrapinarkoc@gmail.com

Bu gruplarda (Hepato-pankreato biliyer tümörler) düşük FDG tutulum etkinliği nedeniyle diğer ajanlarla arayışlar sürmekte olup bu anlamda son yıllarda diğer tümörlerde etkinliğinin gösterilmiş olması bakımından Ga-68 FAPI görüntüleme ön plana çıkmaktadır. Pankreas kanseri ve karaciğer metastazı ile ilgili bir vaka sunumunda (65) ve hepatoselüler karsinom hastalarının dahil edildiği geniş bir seride (66) özellikle yüksek hedef zemin oranı ile tanısal gücünün FDG PET/BT'ye üstünlüğü vurgulanmaktadır.

Kaynaklar

1. Linder G, Korsavidou-Hult N, Bjerner T, et al. ^{18}F-FDG-PET/MRI in preoperative staging of oesophageal and gastroesophageal junctional cancer. Clin Radiol. 2019;74:718-725.
2. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of oesophageal cancer? World J Gastroenterol. 2017;23:751e62.
3. Riddell AM, Davies DC, Allum WH, et al. High-resolution MRI in evaluation of the surgical anatomy of the oesophagus and posterior mediastinum. AJR Am J Roentgenol. 2007;188:W37e43.
4. Lichtenberger JP 3rd, Zeman MN, Dulberger AR, et al. Esophageal Neoplasms: Radiologic-Pathologic Correlation. Radiol Clin North Am. 2021;59:205-217.
5. Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129:1232–1241.
6. Filicori, F,, Swanström, L.L. (2020). Management of esophageal cancer. In: Cameron JL, Cameron AM (Eds). *Current surgical therapy*. (13th ed., pp.53-63). Philadelphia: Elsevier.
7. Little AG, Lerut AE, Harpole DH, et al. The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. Ann Thorac Surg. 2014;98:1880–1885.
8. Betancourt-Cuellar SL, Benveniste MFK, Palacio DP, et al. Esophageal Cancer: Tumor-Node-Metastasis Staging. Radiol Clin North Am. 2021;59:219-229.
9. Little SG, Rice TW, Bybel B, et al. Is FDG-PET indicated for superficial esophageal cancer? Eur J Cardiothorac Surg. 2007;31:791–796.
10. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547–557.
11. Purandare NC, Pramesh CS, Karimundackal G, et al. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma. Nucl Med Commun. 2014;35:864–869.
12. Barber TW, Duong CP, Leong T, et al. 18F-FDG PET/CT has a high impact on patientmanagement and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53:864–871.
13. Lee G, I H, Kim SJ, et al. Clinical implication of PET/MR imaging in preoperative esophageal cancer staging: comparison with PET/CT, endoscopic ultrasonography, and CT. J Nucl Med. 2014;55:1242–1247.
14. Cabral F, Cruz A, R Casaca R, et al. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response. Cancer Radiother. 2020;24:834-841.
15. Weber MA , Bender K, von Gall CC, et al. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction J Gastrointestin Liver Dis. 2013;22:45-52.
16. Hocazade C, Özdemir N, Yazici O, et al. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer. Ann Nucl Med. 2015;29:621–626.
17. Belmouhand M, Löfgren J, Johannesen HH, et al. Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction. Abdom Radiol (NY). 2019;44:836-844.
18. Larsen AC, Hollander C, Duval L, et al. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors. Ann Surg Oncol. 2015;22:1540–1547.
19. Howard BA, Wong TZ. 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. Radiol Clin North Am. 2021;59:737-753.
20. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2- deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776–1785.
21. Smithers BM, Couper GC, Thomas JM, et al. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus. 2008;21:151–158.
22. Kwon HR, Pahk K, Park S, et al. Prognostic value of metabolic information in advanced gastric cancer using preoperative (18)F-FDG PET/CT. Nucl Med Mol Imaging. 2019;53:386–395.
23. Dębiec K, Wydmański J, d'Amico A, et al. The application of ^{18}F-FDG-PET/CT in gastric cancerstaging and factors affecting its sensitivity. Hell J Nucl Med. 2021;24:66-74.

24. Dondi F, Albano D, Giubbini R, et al. 18F-FDG PET and PET/CT for the evaluation of gastric signet ring cell carcinoma: a systematic review. Nucl Med Commun. 2021;42:1293-1300.
25. Park JS, Lee N, Beom SH, et al. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2018; 21:213–224.
26. Pak KH, Yun M, Cheong JH, et al. Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. J Surg Oncol. 2011; 104:566–570.
27. Park YJ, Hyun SH, Moon SH, et al. Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. Sci Rep. 2021;11:9243.
28. Bae SW, Berlth F, Jeong KY, et al. Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer. Gastric Cancer. 2021 Aug 7.
29. Zhang Z , Zheng B , Chen W , et al. Accuracy of ^{18} F-FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta-analysis. Exp Ther Med. 2021;21:164.
30. Zhong BY, Liu YX, Huang WF, et al. Clinical value of 64slice spiral 3phase CT enhanced scanning for preoperative TNM staging assessment of gastric carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15:706709.
31. Tasdemir B, Güzel Y, Komek H, et al. Evaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer. Nucl Med Commun. 2020;41:1322-1327.
32. Liu Q, Li J, Xin B, et al. ^{18} F-FDG PET/CT Radiomics for Preoperative Prediction of Lymph Node Metastases and Nodal Staging in Gastric Cancer. Front Oncol. 2021;11:723345.
33. Farghaly H, Alshareef M, Alqarni A, et al. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions. Eur J Radiol Open. 2020;7:100268.
34. Ertürk SA, Hasbek Z, Özer H. The Relationship Between HER-2 Expression Levels and ^{18}F-FDG PET/CT Parameters in Gastric Cancer. Mol Imaging Radionucl Ther. 2021;30:150-157.
35. Liu G, Yin H, Cheng X, et al. Intra-tumor metabolic heterogeneity of gastric cancer on ^{18} F-FDG PETCT indicates patient survival outcomes. Clin Exp Med. 2021;21:129-138.
36. Şahin E, Elboğa U, Çelen YZ, et al. Comparison of ^{68}Ga-DOTA-FAPI and ^{18}FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur J Radiol. 2021;142:109867.
37. Kou Y, Yao Z, Cheng Z. Al18F-NOTA-FAPI-04 Outperforms 18F-FDG PET/CT in Identifying the Primary Lesion and Rare Metastases From Gastric Cancer. Clin Nucl Med. 2021;46:e570-e571.
38. Chen X, Wei M, Wang S, et al. Characterizing Concomitant Follicular Lymphoma and Gastric Carcinoma Using 68Ga-FAPI-04 and 18F-FDG PET/CT. Clin Nucl Med. 2021 Jun 25.
39. Huang Y, Cao J, Peng D, et al. Bone Marrow Metastases From Gastric Adenocarcinoma on 68Ga-FAPI-04 PET/CT. Clin Nucl Med. 2021 Jul 26.
40. Jiang D , Chen X, You Z, et al. Comparison of [^{68} Ga] Ga-FAPI-04 and [^{18} F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging. 2021 Jul 23.
41. Qin C, Shao F, Gai Y, et al. ^{68}Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with ^{18}F-FDG PET/CT. J Nucl Med. 2021 Apr 16:jnumed.120.258467.
42. Kuten J, Levine C, Shamni O, et al. Head-to-head comparison of [^{68}Ga]Ga-FAPI-04 and [^{18}F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021 Jul 24.
43. Pang Y, Zhao L, Luo Z, et al. Comparison of ^{68}Ga-FAPI and ^{18}F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology. 2021;298:393-402.
44. Fan C, Guo W, Su G, et al. Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT. Clin Nucl Med. 2021;46:e78-e79.
45. Weber SM, Ribero D, O'Reilly EM , et al. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680.
46. Huang X, Yang J, Li J, et al. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2020;99:e20932.
47. Lee Y, Yoo IR, Boo SH, et al. The role of F-18 FDG PET/CT in intrahepatic cholangiocarcinoma. Nucl Med Mol Imaging. 2017;51:69–78.
48. Yoo J, Lee JM, Yoon JH, et al. Additional Value of Integrated ^{18}F-FDG PET/MRI for Evaluating Biliary Tract Cancer: Comparison with Contrast-Enhanced CT. Korean J Radiol. 2021;22:714-724.
49. Ansari D, Keussen I, Andersson R. Positron emission tomography in malignancies of the liver, pancreas and biliary tract - indications and potential pitfalls. Scand J Gastroenterol. 2013;48:259-265.
50. Matsumoto I, Shirakawa S, Shinzeki M, et al. 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:712-718.
51. Wartski M , Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging? Diagn Interv Imaging. 2019;100:735-741.
52. Shrikhande SV, Barreto SG, Goel M, et al. Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the lite rature. HPB (Oxford). 2012;14:658-668.
53. Daamen LA, Groot VP, Goense L, et al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis. Eur J Radiol. 2018;106:128-136.

54. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235–243.
55. Sabaté-Llobera A, Mestres-Martí J, Reynés-Llompart G, et al. 2-[^{18}F]FDG PET/CT as a Predictor of Microvascular Invasion and High Histological Grade in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2021;13:2554.
56. Winkens F , Rudakoff W , Rauchfuss F , et al. FDG PET/CT to Detect Incidental Findings in Patients With Hepatocellular Carcinoma-Additional Benefit for Patients Considered for Liver Transplantation? Clin Nucl Med. 2021;46:532-539.
57. Kawamura Y, Kobayashi M, Shindoh J, et al. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment. Oncology. 2021;99:611-621.
58. Kim K, Kim SJ. Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis. Clin Imaging. 2021;79:251-258.
59. Wang S, Li B, Li P, et al. Feasibility of perfusion and early-uptake ^{18} F-FDG PET/CT in primary hepatocellular carcinoma: a dual-input dual-compartment uptake model. Jpn J Radiol. 2021;39:1086-1096.
60. Young JR, Graham RP, Venkatesh SK, et al. ^{18} F-FDG PET/CT of hepatocellular adenoma subtypes and review of literatüre. Abdom Radiol (NY). 2021;46:2604-2609.
61. Younan G. Pancreas Solid Tumors. Surg Clin North Am. 2020;100:565-580.
62. Basu S, Ranade R, Ostwal V, et al. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clin. 2016;11:233-241.
63. Casadaban LC, Catalano PJ, Lee LK, et al. Assessing ablation margins of FDG-avid liver tumors during PET/CT-guided thermal ablation procedures: a retrospective study. Eur J Nucl Med Mol Imaging. 2021;48:2914-2924.
64. Cazzato RL, Garnon J, Ramamurthy N, et al. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience. Cardiovasc Intervent Radiol. 2016;39:1315-1321.
65. Deng M, Chen Y, Cai L. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Imaging of Pancreatic Cancer With Liver Metastases. Clin Nucl Med. 2021;46:589-591.
66. Wang H, Zhu W, Ren S, et al. ^{68}Ga-FAPI-04 Versus ^{18}F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol. 2021;11:693640.